Literature DB >> 28479227

Limb girdle muscular dystrophy type 2I: No correlation between clinical severity, histopathology and glycosylated α-dystroglycan levels in patients homozygous for common FKRP mutation.

Maisoon Alhamidi1, Vigdis Brox1, Eva Stensland2, Merete Liset3, Sigurd Lindal4, Øivind Nilssen5.   

Abstract

Limb girdle muscular dystrophy type 2I (LGMD2I) is a progressive disorder caused by mutations in the FuKutin-Related Protein gene (FKRP). LGMD2I displays clinical heterogeneity with onset of severe symptoms in early childhood to mild calf and thigh hypertrophy in the second or third decade. Patients homozygous for the common FKRP mutation c.826C>A (p.Leu276Ile) show phenotypes within the milder end of the clinical spectrum. However, this group also manifests substantial clinical variability. FKRP deficiency causes hypoglycosylation of α-dystroglycan; a component of the dystrophin associated glycoprotein complex. α-Dystroglycan hypoglycosylation is associated with loss of interaction with laminin α2, which in turn results in laminin α2 depletion. Here, we have attempted to clarify if the clinical variability seen in patients homozygous for c.826C>A is related to alterations in muscle fibre pathology, α-DG glycosylation levels, levels of laminin α2 as well as the capacity of α-DG to bind to laminin. We have assessed vastus lateralis muscle biopsies from 25 LGMD2I patients harbouring the c.826C>A/c.826C>A genotype by histological examination, immunohistochemistry and immunoblotting. No clear correlation was found between clinical severity, as determined by self-reported walking function, and the above features, suggesting that more complex molecular processes are contributing to the progression of disease.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dystroglycan; FKRP; Laminin α2; Limb girdle muscular dystrophy

Mesh:

Substances:

Year:  2017        PMID: 28479227     DOI: 10.1016/j.nmd.2017.02.015

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  14 in total

1.  A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.

Authors:  Peter R Serafini; Michael J Feyder; Rylie M Hightower; Daniela Garcia-Perez; Natássia M Vieira; Angela Lek; Devin E Gibbs; Omar Moukha-Chafiq; Corinne E Augelli-Szafran; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel; Matthew S Alexander
Journal:  JCI Insight       Date:  2018-09-20

2.  Diagnostic muscle biopsies in the era of genetics: the added value of myopathology in a selection of limb-girdle muscular dystrophy patients.

Authors:  Boel De Paepe; Elise Velghe; Linnea Salminen; Balint Toth; Pieter Olivier; Jan L De Bleecker
Journal:  Acta Neurol Belg       Date:  2021-01-05       Impact factor: 2.396

Review 3.  Fukutin-Related Protein: From Pathology to Treatments.

Authors:  Carolina Ortiz-Cordero; Karim Azzag; Rita C R Perlingeiro
Journal:  Trends Cell Biol       Date:  2020-12-01       Impact factor: 20.808

4.  FKRP-dependent glycosylation of fibronectin regulates muscle pathology in muscular dystrophy.

Authors:  A J Wood; C H Lin; M Li; K Nishtala; S Alaei; F Rossello; C Sonntag; L Hersey; L B Miles; C Krisp; S Dudczig; A J Fulcher; S Gibertini; P J Conroy; A Siegel; M Mora; P Jusuf; N H Packer; P D Currie
Journal:  Nat Commun       Date:  2021-05-19       Impact factor: 14.919

Review 5.  The roles of dystroglycan in the nervous system: insights from animal models of muscular dystrophy.

Authors:  Alec R Nickolls; Carsten G Bönnemann
Journal:  Dis Model Mech       Date:  2018-12-19       Impact factor: 5.758

6.  Clinical, genetic, and pathologic characterization of FKRP Mexican founder mutation c.1387A>G.

Authors:  Angela J Lee; Karra A Jones; Russell J Butterfield; Mary O Cox; Chamindra G Konersman; Carla Grosmann; Jose E Abdenur; Monica Boyer; Brent Beson; Ching Wang; James J Dowling; Melissa A Gibbons; Alison Ballard; Joanne S Janas; Robert T Leshner; Sandra Donkervoort; Carsten G Bönnemann; Denise M Malicki; Robert B Weiss; Steven A Moore; Katherine D Mathews
Journal:  Neurol Genet       Date:  2019-03-01

7.  Duchenne muscular dystrophy-like phenotype in an LGMD2I patient with novel FKRP gene variants.

Authors:  Tetsuya Okazaki; Kaori Matsuura; Noriko Kasagi; Kaori Adachi; Masachika Kai; Mariko Okubo; Ichizo Nishino; Eiji Nanba; Yoshihiro Maegaki
Journal:  Hum Genome Var       Date:  2020-04-20

8.  Magnetic Resonance Imaging Findings in the Muscle Tissue of Patients with Limb Girdle Muscular Dystrophy Type 2I Harboring the Founder Mutation c.545A>G in the FKRP Gene.

Authors:  Zhiying Xie; Jiangxi Xiao; Yiming Zheng; Zhaoxia Wang; Yun Yuan
Journal:  Biomed Res Int       Date:  2018-05-29       Impact factor: 3.411

9.  Cardiomyopathy in limb girdle muscular dystrophy R9, FKRP related.

Authors:  Eric M Libell; Julia A Richardson; Katie L Lutz; Benton Y Ng; Shelley R H Mockler; Katie M Laubscher; Carrie M Stephan; Bridget M Zimmerman; Erik R Edens; Benjamin E Reinking; Katherine D Mathews
Journal:  Muscle Nerve       Date:  2020-09-10       Impact factor: 3.217

10.  A universal gene correction approach for FKRP-associated dystroglycanopathies to enable autologous cell therapy.

Authors:  Neha R Dhoke; Hyunkee Kim; Sridhar Selvaraj; Karim Azzag; Haowen Zhou; Nelio A J Oliveira; Sudheer Tungtur; Carolina Ortiz-Cordero; James Kiley; Qi Long Lu; Anne G Bang; Rita C R Perlingeiro
Journal:  Cell Rep       Date:  2021-07-13       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.